Adis Journals and Newsletters The premier collection of drug-focused medical journals
|
|
- Job Watkins
- 5 years ago
- Views:
Transcription
1 adis.com Adis Journals and Newsletters The premier collection of drug-focused medical journals An invaluable resource for all involved in medical research, practice or teaching, drug regulation or reimbursement, or the pharmaceutical industry Independent and reputable publishers of high quality medical journals for over 40 years Unique content from the experienced in-house Adis Drug Review team Invited review articles summarize complex and broad topics for your end-users Cutting-edge original research in all therapy areas All Adis journal and newsletter content is available on SpringerLink, Springer for R&D, and Springer for Hospitals & Health. These robust, mobile-optimized platforms enable your end users to access over 8 million research documents anytime, anywhere, including thousands of ebooks and more than 400 journals relevant to medical research.
2 Adis Journals adis.com Clinical Pharmacology and Therapy Drugs Setting the standards in reviews of all aspects of clinical pharmacology since 1971 Definitive reviews of drugs and drug classes, and their place in disease management including systematic reviews and meta-analyses Pivotal original research Advances in Therapy Clinical Drug Investigation Dedicated to rapid publication of studies in clinical medicine Reviews and original research across a broad range of therapeutic areas Evaluation of existing and new drug therapies, diagnostics, instrumentation and related fields Enhanced features such as summary slides and animations reinforce reader understanding A journal focused on clinical investigations of drugs and drug devices Efficacy and safety data from a wide range of clinical trials Outcomes research and pharmacoeconomics studies included Pharmaceutical Medicine 0.553* Disseminates the latest information on the optimal conduct of clinical studies Contributions from top industry physicians, regulators and academics Topics include regulatory science, pharmacovigilance, ethics, pharmacology and trial design due 2016 Drugs & Therapy Perspectives N/A Authoritative yet easy-to-read review articles to aid drug formulary and prescribing decisions New developments and international consensus on drug therapy Guidance on management of adverse drug reactions and interactions Pharmacoeconomics and outcomes research that impacts on clinical practice Pharmacokinetics Clinical Pharmacokinetics European Journal of Drug Metabolism and Pharmacokinetics Making sense of pharmacokinetic, pharmacodynamic, and pharmacogenetic data Emphasis on clinical data in special populations including those with hepatic or renal impairment, women, children, and the elderly Evidence-based authoritative reviews on new drugs and drug classes Comprehensive journal covering all aspects of pharmacokinetics including drug interactions, bioavailability, and biopharmacy Original research and review articles on special topics Conference proceedings *The SCImago Cites per Doc. (2y) measures the scientific impact of a journal using the same formula as the Impact but using the Scopus database 2
3 adis.com Adis Journals Specialist Therapy Areas Impact Description CNS Drugs Drug developments in both neurology and psychiatry Seminal reviews summarizing wide-ranging and complex original research findings Succinct guidance on the place of new drugs in clinical practice Publishes important original research Targeted Oncology A journal for all healthcare professionals in the field of oncology Reviews of new treatments including monoclonal antibodies and small molecules Insights into the clinical implications of research into new targets for cancer therapy American Journal of Clinical Dermatology American Journal of Cardiovascular Drugs Content selected to promote evidence-based therapy and effective patient management in clinical dermatology Definitive reviews on management of dermatological conditions Clinically relevant original research articles Strong focus on clinical management of cardiovascular disorders Evidence-based evaluation of novel drugs and new targets Original clinical and pharmacoeconomic research useful for administrators and decision makers High Blood Pressure & Cardiovascular Prevention 1.200* Expert commentary on guidelines and clinical trials Time-saving reviews on research into cardiovascular disease prevention Insights into socioeconomic issues surrounding cardiovascular disease Proceedings of scientific meetings Special Patient Populations Drugs & Aging Focused on clinical management of diseases with particular relevance to older adults Comprehensive reviews and original research promoting optimum drug prescribing and utilization in older patients Clinical implications of age-related physiological changes for drug therapy Pediatric Drugs Clinical issues affecting drug therapy in children and adolescents Efficacy and safety of drugs at all stages of pediatric development Addresses optimal formulations and drug delivery in children Includes issues surrounding drug access, pharmacogenomics and costs *The SCImago Cites per Doc. (2y) measures the scientific impact of a journal using the same formula as the Impact but using the Scopus database 3
4 adis.com Adis Journals Health Economics and Outcomes Resarch Pharmaco- Economics The Patient: Patient-Centered Outcomes Research Applied Health Economics and Health Policy Original research on the cost-effectiveness of drug therapy Authoritative reviews on issues related to scarce allocation of resources and formulary management Allows decision makers to critically evaluate and comprehend complex pharmacoeconomic reports Ground-breaking journal published in association with Johns Hopkins University Illuminates what patients value in their treatment, and what drives adherence Provides the latest research on patient-reported outcomes Covers risk communication, shared decision making, and health literacy 1.710* Guide to efficient resource allocation and decision making Economic assessment of various healthcare interventions, systems and policies Range of perspectives, from individual institutions to whole countries Pharmaco- Economics & Outcomes News N/A Concise summaries on the latest issues in health economics and outcomes news Economic impact of drugs, diseases, devices, diagnostics and screening protocols, prescribing and drug utilisation trends, quality-of-life effects of drugs,reimbursement decisions, and health policy and reforms Pharmacovigilance Impact Description Drug Safety Reviews by leading physicians and academics on benefit-risk assessment, risk management, medication error prevention, and pharmacoepidemiology Specific information on drug use in at-risk patient groups, editorials and commentaries on topical issues, and original research Reactions Weekly N/A A weekly round-up of adverse drug reaction news including pharmacovigilance, regulatory, research, and current opinion Published adverse event case reports, labelling changes, drug withdrawals, and drug safety research First published, drug overdose and drug interaction case reports highlighted for easy reference *The SCImago Cites per Doc. (2y) measures the scientific impact of a journal using the same formula as the Impact but using the Scopus database 4
5 Adis Journals adis.com Biotechnology and Precision Medicine Impact Description BioDrugs Independent, definitive reviews on the place of new biologics in clinical practice Stem cell therapies Emerging treatment strategies and comparative effectiveness Molecular Diagnosis & Therapy A journal devoted to the field of personalized medicine Simplifies complex research on biomarkers, pharmacogenomics, and molecular diagnostics Evaluations of drug/diagnostic combinations Genetic factors affecting response to drug therapy Key for tables on pages 2, 3, 4 and 5 Ranked in top 50 of relevant ISI category 18 Adis premier journals indexed in Adis Drug Reviews Adis Drug Reviews are a unique range of definitive drug assessments written by a specialist in-house team and rigorously peer reviewed by international experts. For more than 40 years these Drug Reviews have been a trusted resource for healthcare practitioners, giving clear guidance on an agent s place in therapy. The Adis Drug Review program aims to provide readers with the most important and clinically relevant information on the properties of new and established drugs, across all therapeutic areas, and are included in 11 of the Adis Premier Journals. Adis Drug Evaluations Definitive reviews of pharmacological properties, clinical efficacy and tolerability of new and established drugs Critical evaluation of the most important data Define clinical potential/most appropriate place in therapy AdisInsight Reports Published shortly after the drug receives approval in its first indication in any market Brief review of development history, pharmacological properties, clinical efficacy and tolerability Based on drug information from the proprietary AdisInsight database Adis Drug Q&As Succinct reviews of pharmacological properties, clinical efficacy and tolerability for the busy practicing clinician or other healthcare professional Evidence-based and focus on the practical use of drugs in the clinical setting New and established drugs 5
6 Adis Journals adis.com Adis Journal Archive Archive content from 23 high quality Adis Journals and Newsletters including discontinued titles, dating from 1971 Also available on the SpringerLink, Springer for R&D, and Springer for Hospitals & Health platforms Complete, ongoing access for your readers Open Access Journals Our Adis Premier Journals are accompanied by a suite of open access journals: the Adis Open and Adis Rapid+ titles. Content includes preclinical, clinical and real-world research in medicine, covering existing and developmental drugs across all therapeutic areas. The journals publish original research, reviews, case reports, and short communications, and are of interest to a wide range of pharmaceutical and healthcare professionals. Adis Open journals include: Drugs in R&D, Drugs - Real World Outcomes and Drug Safety - Case Reports. Adis Rapid+ journals include: Cardiology and Therapy, Dermatology and Therapy, Diabetes Therapy, Infectious Diseases and Therapy, Neurology and Therapy, Ophthalmology and Therapy, Pain and Therapy, Pulmonary Therapy, Rare Cancers and Therapy, and Rheumatology and Therapy. AdisInsight Make great discoveries possible in your organization with expertly written content to support drug research and development, disease treatment and decision making. AdisInsight delivers the most compelling, current scientific and commercial information on drugs in development worldwide, clinical trials, deals and safety reports, in a single easy-to-use database. Would you like to know more? Contact Springer today. Visit springer.com/salescontacts to find your local Springer representative! Would you like to know more? Contact Springer today. Visit springer.com/salescontacts to find your local Springer representative! A01002R3 COR-136 Images: page 1: Roman Ponomarets/iStockphotos page5: PTter Gudella/iStockphotos page 6: gualtiero boffi/fotolia A01002R3 COR-77 C Images: page 1: Roman Ponomarets / istockphotos; page5: PTter Gudella; istockphotos; page 6: gualtiero boffi / Fotolia Contact us! Contact us!
Illustration inspired by the work of John Maynard Keynes Springer Nature Nano/AdisInsight. Daria Iovcheva November, 2017
Illustration inspired by the work of John Maynard Keynes Springer Nature Nano/AdisInsight Daria Iovcheva November, 2017 1 Contents 1.0 About Springer Nature and our platforms 2.0 Nature Research Journals:
More informationLet us empower you to be a pharmacovigilance superhero...
Let us empower you to be a pharmacovigilance superhero... Concise, up-to-date and reliable adverse event information that can be used for many different pharmacovigilance activities. Pharmacovigilance
More informationEXPERT COLLECTION. Explore our leading medical review series
EXPERT COLLECTION Explore our leading medical review series Introducing the EXPERT COLLECTION The Taylor & Francis Expert Collection is the world s largest series of review journals in research, development,
More informationadis.com Custom Intelligence Focus on your strategic decisions Learn More
Custom Intelligence Focus on your strategic decisions Learn More Focus on Your Strategic Decisions Rely on Adis, the company trusted worldwide for its drug, clinical trial, and adverse event databases,
More informationAT A GLANCE. inventivhealthclinical.com
AT A GLANCE inventivhealthclinical.com 1 Table of Contents OVERVIEW 02 PHASE I-IIA 03 PHASE IIB-III 04 LATE STAGE 05 STRATEGIC RESOURCING 06 BIOANALYTICAL 07 QUALITY ASSURANCE 08 CONSULTING 09 THERAPEUTIC
More informationFuture Science Group VISION IN STM PUBLISHING [ BARBARA VALCELLI / ACCUCOMS
Future Science Group VISION IN STM PUBLISHING [ BARBARA VALCELLI / ACCUCOMS BARBARA@ACCUCOMS.COM Publisher of journals, ebooks and ecommunities Introducing Future Science Group About Future Science Group
More informationReport from the Paediatric Committee on its first anniversary
European Medicines Agency London, 11 July 2008 Doc. Ref. EMEA/PDCO/347884/2008 Report from the Paediatric Committee on its first anniversary The European Medicines Agency s Paediatric Committee (PDCO)
More informationList of E-journals Subscribed for the year 2016 (January to December) Pharmacy Faculty Sl. No.
Faculty 1 Adolescent Psychiatry Psychiatry 2 Anti Cancer Agents in Medicinal / Pharma & Quality 3 Anti-Infective Agents Pharmaceutical Microbiology 4 Anti-Inflammatory & Anti- Allergy Agents in Medicinal
More informationSciTechnol Mediakit. MatheMatics. Research and Reports on. Research Journal of Clinical Pediatrics
SciTechnol Mediakit Research Journal of Clinical Pediatrics Research and Reports on MatheMatics www.scitechnol.com www.scitechnol.com Our Vision To publish, promote and disseminate the work of medical
More informationAdis Journals Overview
Adis Journals Overview Introduction Adis Rapid Publishing Service Life after publication AdisOnline.com The Adis publishing heritage The Adis Journals brand has evolved over 40 years to become synonymous
More informationEarly Patient Studies in Evolution. John Horkulak Executive Director, Eurasian External Study Operations Feb 23, 2015
Early Patient Studies in Evolution John Horkulak Executive Director, Eurasian External Study Operations Feb 23, 2015 Questions How are early phase studies evolving and why the push for studying patients
More information'PHARMACOLOGY%20%26%20PHARMACY'
Journal Data Filtered By: Selected JCR Year: 2014 Selected Editions: SCIE Selected Categories: 'PHARMACOLOGY%20%26%20PHARMACY' Selected Category Scheme: WoS Rank Full Journal Title Total Cites Journal
More informationSSPPS STRATEGIC PLAN. Pharmacy Education, Pharmaceutical Sciences Research, Clinical Pharmacy Practice. April 30, Overview
SSPPS STRATEGIC PLAN Pharmacy Education, Pharmaceutical Sciences Research, Clinical Pharmacy Practice April 30, 2012 Overview Here we present the 2012-2017 strategic plan for the Skaggs School of Pharmacy
More informationSaudi Pharmacist Licensure Examination (SPLE)
Saudi Pharmacist Licensure Examination (SPLE) 1 SPLE Overview This document provides important information about the topics covered on the examination and the competency areas in which candidates will
More information3rd Global Congress On Medical & Clinical Case Reports Theme: Medical & Clinical Exploration By Global Experts About the Conference: Aim
3rd Global Congress On Medical & Clinical Case Reports Theme: Medical & Clinical Exploration By Global Experts About the Conference: Gavin Conferences invites participants from all over the world to attend
More informationThis template is to be used by companies willing to submit an overview of relevant
Briefing book template for pharmaceuticals to support a multi-hta Early Dialogue (ED) December 13 th, 2013 This template is to be used by companies willing to submit an overview of relevant information
More informationDoctor of Pharmacy Course Descriptions
Doctor of Pharmacy Course Descriptions Required Courses Pharmacy Practicum II (7002) Second practicum with direct instruction by an experienced preceptor to increase the student's awareness of the pharmacist's
More informationDrug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities
More informationGenomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development)
Genomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development) Strategies for modern biomarker and drug - Oct 3, 2014 Sequencing the cancer genome
More informationIndustry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
More informationThe NHS approach to personalised medicine in respiratory disease. Professor Sue Chief Scientific Officer for England
The NHS approach to personalised medicine in respiratory disease Professor Sue Hill @CSOSue Chief Scientific Officer for England Jul 2017 Genomics is probably the biggest breakthrough in the last 50 years.
More informationWhile individually rare, orphan diseases are actually collectively common, with an OF ORPHAN DRUG DEVELOPMENT MEETING THE UNIQUE CHALLENGES
ELECTRONICALLY REPRINTED FROM JUNE 2017 CLINICAL TRIALS Rare Diseases: MEETING THE UNIQUE CHALLENGES OF ORPHAN DRUG DEVELOPMENT BY MICHAEL F. MURPHY, MD, Ph D While individually rare, orphan diseases are
More informationImportance of Pharmacovigilance for Pharmaceutical Industry
Importance of Pharmacovigilance for Pharmaceutical Industry JARIR AT THOBARI, MD, DPHARM, PHD FACULTY OF MEDICINE GADJAH MADA UNIVERSITY YOGYAKARTA, INDONESIA Role of Pharma Company Globally Investment
More informationDocket #: FDA-2018-D-3268
Subject: Comment on FDA Draft Guidance for Industry Titled Rare Diseases: Early Drug Development and the Role of Pre-Investigational New Drug Application Meetings Docket #: FDA-2018-D-3268 ARM is an international
More informationNIH-RAID: A ROADMAP Program
NIH-RAID: A ROADMAP Program (Rapid Access to Interventional Development} A Program designed to facilitate the development of new therapeutics The NIH-RAID Pilot Program is intended to reduce some of the
More informationContent Areas of the Pharmacy Curriculum Outcomes Assessment (PCOA )
Content Areas of the Pharmacy Curriculum Outcomes Assessment (PCOA ) Area 1.0 Basic Biomedical Sciences (10%) Area 2.0 Pharmaceutical Sciences (33%) Area 3.0 Social/Behavioral/Administrative Sciences (22%)
More informationHeader. Future Science Group. Catalogue 2019
Header Future Science Group Catalogue 2019 1 Section Header 2 For more information visit www.future-science-group.com Contents Page Our Journal Portfolio 2 Future Medicine At-A-Glance 3 Future Science
More informationWorkshop on Access to and Uptake of Biosimilar Medicinal Products
EUROPEAN COMMISSION Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Biotechnology and Food Supply Chain Workshop on Access to
More information5 key characteristics
Biosimilars 5 key characteristics Biologics are medicinal products derived from living organisms. 1 Their use has impacted the treatment of a variety of diseases. 1 Patents for many biologics will soon
More informationEU support for Health Research from FP6 to FP7
EU support for Health Research from FP6 to FP7 Stéphane Hogan Head of Biotechnology Unit Directorate for Health Research DG Research - European Commission Valencia - 15 September 2006 EU research programmes
More informationRWE from pre-clinical to launch. RWE from pre-clinical to launch. Standard of care Unmet needs. Disease burden Budget impact.
Real Real World World Data Data Across Across the the Product Product Lifecycle: Lifecycle: RWE from pre-clinical to launch RWE from pre-clinical to launch Standard of care Unmet needs Disease burden Budget
More informationDefining the Expertise for the 21 st Century Neuroscience Workforce. James E. Barrett, Ph.D. Professor and Chair
Defining the Expertise for the 21 st Century Neuroscience Workforce James E. Barrett, Ph.D. Professor and Chair Department of Pharmacology and Physiology Drug Discovery and Development Program at Drexel
More informationAgreed with W. Cornell Graduate Program and Tri-I
Drug Development Course From Molecule to Prescription Weill Cornell Graduate School - Tri-Institutional Therapeutics Discovery Institute ABOUT THIS COURSE This course has been designed in collaboration
More informationAPPLICATION FOR PAEDIATRIC INVESTIGATION PLAN / WAIVER
Version-number 3.0.0 APPLICATION FOR PAEDIATRIC INVESTIGATION PLAN / WAIVER This application is submitted for a: Medicinal Product for which the Applicant does not hold a marketing authorisation in the
More informationMolecular Diagnostics
Molecular Diagnostics Part II: Regulations, Markets & Companies By Prof. K. K. Jain MD, FRACS, FFPM Jain PharmaBiotech Basel, Switzerland May 2018 A Jain PharmaBiotech Report A U T H O R ' S B I O G R
More informationMay 23, :30 PM-5:00 PM - AUDITORIUM A250. May 9, :30 PM -5:00 PM - AUDITORIUM A-950 May 16, :30 PM-5:00 PM - AUDITORIUM A250
DRUG DEVELOPMENT COURSE - FROM MOLECULE TO PRESCRIPTION WEILL CORNELL GRADUATE SCHOOL - TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE THURSDAYS FROM 3:00PM - 5:00PM AT 1300 YORK AVE, NEW YORK, N.Y.
More informationCompany Profile. German-Taiwan Biotech Seminar 6 November 2017
Company Profile German-Taiwan Biotech Seminar 6 November 2017 Our Mission Bayer: Science For A Better Life A growing and aging world population requires an adequate supply of food and improved medical
More informationMay 9, Meeting Summary. Facilitating Antibacterial Drug Development
May 9, 2012 Meeting Summary Facilitating Antibacterial Drug Development Origins of the Current Public Health Crisis of Antibacterial Resistance Antibacterial drugs play a critical role in the ability to
More informationA. TRIAL IDENTIFICATION
PROTOCOL INFORMATION ON A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE CONDUCTED IN A THIRD COUNTRY (i.e. a country outside of the EEA) Note: To ensure consistency the numbering of this form is
More informationOPTIMAL USE PROGRAM DRUG Therapeutic Review Framework and Process
OPTIMAL USE PROGRAM DRUG Therapeutic Review Framework and Process Version: 3.0 Publication Date: June 27, 2018 Report Length: 16 Pages Revision History From time to time, CADTH may amend the therapeutic
More informationPost-marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER
Post-marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER CSRC/DIA Think Tank June 3, 2016 Oanh Dang, PharmD, BCPS Division of Pharmacovigilance Safety Evaluator Office of Surveillance and
More informationThe Seventh Framework Programme ( )
The Seventh Framework Programme (2007-2013) Opportunities for Cardiovascular Research 1 Octavi Quintana Trias, MD, MPH Director Health DG Research - European Commission Octavi.Quintana-Trias@ec.europa.eu
More informationTrend in diagnostic biochip. Eiichiro Ichiishi, M.D., Ph.D. Department of Internal Medicine International University of Health and Welfare Hospital
Trend in diagnostic biochip development Eiichiro Ichiishi, M.D., Ph.D. Department of Internal Medicine International University of Health and Welfare Hospital Handling of the early stage is important for
More informationPersonalized. Health in Canada
Personalized Health in Canada Canadian Institutes of Health Research Personalized Medicine Signature Initiative 2010-2013 0 Dr. Morag Park CIHR Institute of Cancer Research Dr. Paul Lasko CIHR Institute
More informationHow are medicines evaluated at the EMA
How are medicines evaluated at the EMA Presented by: Nathalie Bere Patient interaction / Stakeholders and communication Division An agency of the European Union The European System Centralised Procedure
More informationGenomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development) READ ONLINE
Genomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development) READ ONLINE to modify patients' exposure to drugs based on their genomic drug-response
More informationInvestigational New Drug Application
Investigational New Drug Application Regulatory Sponsor: Funding Sponsor: Study Product: Protocol Number: Name of the Sponsor-Investigator Department Name Address Phone Number Name of Primary Funding Institution
More informationNIHR Cambridge Clinical Research Facility
NIHR Cambridge Clinical Research Facility National Institute for Health Research The perfect environment for experimental medicine studies and early phase clinical trials for Life Sciences, Biotech and
More informationDate/Lecturer Class Topic Readings 01/28/10 Brookman
Course Director: Sheldon, Ph.D. 01/28/10 1 I. Course Description and Requirements II. Historical Perspectives and Overview of Drug Development a. Evolution of the pharmaceutical industry b. Changing development
More informationInternational Conference on Pharmacy and Pharmaceutical Sciences April 09-11, 2018, Dubai UAE
International Conference on Pharmacy and Pharmaceutical Sciences April 09-11, 2018, Dubai UAE EMAIL: pharmacy@citationsinternational.com VISIT OUR WEBSITE: https://www.citationsinternational.com/pharmacy-conference-2018#about
More informationTHERAPEUTIC AREAS CARDIOVASCULAR RESEARCH
THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH PPD S CARDIOVASCULAR TEAM: OPTIMIZING TRIALS AND IMPROVING OUTCOMES APPLYING EXPERIENCE, INNOVATION AND EFFICIENCY IN THE FIGHT AGAINST CARDIOVASCULAR DISEASE
More informationIntroduction to clinical trials
Introduction to clinical trials Definition of a clinical trial A research activity that involves administration of a test treatment to some experimental unit in order to evaluate the treatment. Key words
More informationMaximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date
F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report
More informationValuing Healthcare Biotechnology in Europe: EuropaBio s perspective
Valuing Healthcare Biotechnology in Europe: EuropaBio s perspective The healthcare biotechnology sector The healthcare biotechnology sector includes bioscience based enterprises, which create and deliver
More informationIntroduction to clinical trials Magnus Kjaer
Introduction to clinical trials 2016-01-20 Magnus Kjaer One Definition of Clinical Trial NIH 2014 A research study in which one or more human subjects are prospectively assigned to one or more interventions
More informationSpringer Protocols. springer.com. Introducing the world s most comprehensive collection of peer-reviewed life sciences protocols
springer.com Springer Protocols Introducing the world s most comprehensive collection of peer-reviewed life sciences protocols 7 More than 18,000 protocols with an additional 2,000 added each year 7 Based
More informationLead the way. Molecular Imaging. GE Healthcare. imagination at work
2010 General Electric Company All rights reserved. General Electric Company reserves the right to make changes in specifications and features shown herein, or discontinue the product described at any time
More informationMain Content Domain % of Operational Items # of Operational Items
The PCOA content areas and subtopics for the 2016-2017 administration are based upon the outcomes from the US College of Pharmacy Curricula Survey. The assessment is composed of four content areas that
More informationSummary of Product Characteristics Advisory Group (SmPC AG) activity report
14 March 2016 Scientific and Regulatory Management Department Summary of Product Characteristics Advisory Group (SmPC AG) 2010-2015 activity report Quality assurance of SmPCs 1. Introduction During the
More informationPrecision Medicine. Presented by:
Precision Medicine Presented by: Prepared Brendan FitzGerald For: Enabling better health through information technology. Healthcare Information and Management Systems Society (HIMSS) HIMSS is a global,
More informationThe Need for National Pharmacovigilance Program
The Need for National Pharmacovigilance Program ANAS BAHNASSI Presented at Order of Lebanese Pharmacists on March 10 th 2018 All drugs are dangerous Some are also useful. N. Moore, BMJ, 2005, 330;539-540
More informationNeurodegeneration and other neuroscience priorities
Potential future IMI Call topics About this document The following topics are under consideration for inclusion in future IMI Calls for proposals in the longer term. The discussions on these topics are
More informationUNDERGRADUATE AND PROFESSIONAL MAJOR CHANGE BULLETIN NO. 9 Spring Faculty Senate Approved April 11, COURSES---
UNDERGRADUATE AND PROFESSIONAL MAJOR CHANGE BULLETIN NO. 9 Spring 2013 Faculty Senate Approved April 11, 2013 ---COURSES--- The courses listed below reflect the undergraduate major curricular changes approved
More informationBayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms
Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms Genomics Bioinformatics HTS Combinatorial chemistry Protein drugs
More informationFrom IMI to IMI2 new models of collaborative research. Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014
From IMI to IMI2 new models of collaborative research Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014 What is IMI and how does it work? Innovative Medicines Initiative: Joining Forces in the
More informationEarly Phase Education WHITEPAPER. Three major items to consider when moving from preclinical to clinical development
Early Phase Education WHITEPAPER Three major items to consider when moving from preclinical to clinical development Three major items to consider when moving from preclinical to clinical development Dr.
More informationPolicies Approved by the 2018 ASHP House of Delegates
House of Delegates Policies Approved by the 2018 ASHP House of Delegates 1801 Unit Dose Packaging Availability To advocate that pharmaceutical manufacturers provide all medications used in health systems
More informationStatement on Regulatory Systems to Improve Pharmaceutical Safety
International Society for Pharmacoepidemiology (ISPE) Statement on Regulatory Systems to Improve Pharmaceutical Safety INTRODUCTION The public, some researchers, individual regulators and policymakers
More informationThe future is. Personalized Medicine.
The future is Personalized Medicine. What is Pharmacogenomics (PGx)? Pharmacogenomics and Personalized Medicine Patient Adherence Many commonly prescribed medications used to treat everyday ailments can
More informationCourse Agenda. Day One
Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an
More informationPharmaceuticals and Biotechnology
ABCD Pharmaceuticals and yet are quickly accessible from one central location. 7 Gain a competitive advantage 7 Facilitate product research and development 7 Raise return on investment Pharmaceuticals
More informationHow Targets Are Chosen. Chris Wayman 12 th April 2012
How Targets Are Chosen Chris Wayman 12 th April 2012 A few questions How many ideas does it take to make a medicine? 10 20 20-50 50-100 A few questions How long does it take to bring a product from bench
More informationDEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE WHEN COMMERCIALIZING A MEDICINE, IT
More informationThe role of patients at the EMA
The role of patients at the EMA Nathalie Bere Patient relations coordinator / European Medicines Agency An agency of the European Union What is the European Medicines Agency (EMA) The EMA is the EU regulatory
More informationIBM Micromedex care delivery Evidence-based clinical decision support for healthcare decision-makers
IBM Micromedex care delivery Evidence-based clinical decision support for healthcare decision-makers WELLNESS AND PREVENTION REDUCING COSTS BETTER USE OF PATIENT DATA AND ANALYTICS IMPROVING QUALITY OF
More informationASBM Biosimilars. Canada Prescribers and Biosimilars October, Kevin Olson, CEO Industry Standard Research
ASBM Biosimilars Canada Prescribers and Biosimilars October, 2017 Kevin Olson, CEO Industry Standard Research KevinO@ISRreports.com Table of contents Page 3 Methodology 5 Sample Characteristics 6 Executive
More informationAccelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective
Accelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective Imran M. Khan, Ph.D. Division of Psychiatry Center for Drug Evaluation and Research FDA
More informationAbout OMICS Group Conferences
About OMICS Group OMICS Group International is an amalgamation of Open Access publications and worldwide international science conferences and events. Established in the year 2007 with the sole aim of
More informationBelgium, a European leader in clinical trials
Belgium, a European leader in clinical trials An attractive country for clinical trials to test innovative medicines In Europe it is nearly impossible to find other countries with as many clinical trials
More informationManaging Risk and Uncertainty Through the Drug Life cycle. Recent FDA Initiatives. Theresa Mullin, PhD
Managing Risk and Uncertainty Through the Drug Life cycle Recent FDA Initiatives Theresa Mullin, PhD Director Office of Strategic Programs US FDA Center for Drug Evaluation and Research October 14, 2014
More informationTHE IMPACT OF ADR REPORTING ON SAFE USE OF MEDICINES IN SINGAPORE THE 10-YR EXPERIENCE
THE IMPACT OF ADR REPORTING ON SAFE USE OF MEDICINES IN SINGAPORE THE 10-YR EXPERIENCE Dr John Lim Dr John Lim Chief Executive Officer Health Sciences Authority Singapore 13 October 2006 Ms Chan Cheng
More informationYOUR FIRST CHOICE FOR IN-OFFICE GENETIC TESTING
YOUR FIRST CHOICE FOR IN-OFFICE GENETIC TESTING THE NEW STANDARD OF CARE WHY GENETIC TESTING? Genetic testing makes it possible to know a priori how your patients will metabolize a specific drug. It is
More informationSpecialty Pharmacy 101
Specialty Pharmacy 101 The Landscape of Specialty Pharmacy Services DATE: October 27, 2011 NAME: TITLE: Clinical Pharmacist, Serve You Agenda Define specialty pharmacy Examine market trends and current
More informationInnovative Medicines Initiative (IMI) Future funding opportunities. Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017
Innovative Medicines Initiative (IMI) Future funding opportunities Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017 Outline What is IMI and why do we need it? How does IMI work?
More informationMPharm programme in Pharmacovigilance and Pharmacoepidemiology
MPharm programme in Pharmacovigilance and Pharmacoepidemiology Prof Martie S Lubbe Director: Medicine Usage in South Africa Faculty of Health Sciences Medicine Usage in South Africa Research focus has
More informationFIRST YEAR PHARM. D. Know about the theory and their application in pharmacy PDM107 Remedial Mathematics
PDL101 Human Anatomy and Physiology FIRST YEAR PHARM. D Students learn the basic concepts of human organ, location, function, parts with model PDP102 Pharmaceutics Students will be exposed to various dosage
More informationPharmamarketing - strategic challenges
Pharmamarketing - strategic challenges Biomedicine Master Program Lund University Course: Biomedicine the Profession Anna Chérouvrier Hansson, MSc. December 16th, 2014 1. Pharmamarketing - definitions
More informationUniversità Cattolica del Sacro Cuore
Università Cattolica del Sacro Cuore The role of Regulatory Affairs in drug development Francesco Mazza, Director of Legal, Fiscal & Compliance Affairs in Farmindustria Rome, May 12 2017 Who we are Who
More informationOFFICE FOR RESEARCH PROCEDURE PROTOCOL & INVESTIGATIONAL BROCHURE, CONTENT, DESIGN, AMENDMENTS & COMPLIANCE
OFFICE FOR RESEARCH PROCEDURE PROTOCOL & INVESTIGATIONAL BROCHURE, CONTENT, DESIGN, AMENDMENTS & COMPLIANCE 1. Purpose: To describe the procedures related to the development of protocol and investigational
More informationProgram of study. pharmacy. 1st year
II I Program of study pharmacy 1st year Anatomy 15-15 GC Biophysics 15 15 - E Biology and Genetics 60 15 15 E 4 Botany 90 45 15 E 7 Analytical I 4 1 - E General and Inorganic 105 45 E 7 Latin Course -
More informationNHS ENGLAND BOARD PAPER
NHS ENGLAND BOARD PAPER Paper: PB.30.03.2017/06 Title: Creating a genomic medicine service to lay the foundations to deliver personalised interventions and treatments Lead Director: Professor Sir Bruce
More informationCL1 : Molecular imaging for diagnosis and treatment of neurodegenerative disorders at a prodromal stage CL2 : The role of non-coding RNAs in
CL1 : Molecular imaging for diagnosis and treatment of neurodegenerative disorders at a prodromal stage CL2 : The role of non-coding RNAs in malignant cardiac diseases CL3 : Large scale optical imaging
More informationDelivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y
Delivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y PERSPECTIVE/ DISCLAIMERS Doctor with >24 years experience
More informationWebinar: Knowledge-based approaches to decreasing clinical attrition rates
Webinar: Knowledge-based approaches to decreasing clinical attrition rates Speakers: Dr. Richard K. Harrison Gavin Coney Teresa Fishburne May 2018 2 Clarivate Analytics is the global leader in providing
More informationAbout Clinical Trials: What They Can Mean For You?
About Clinical Trials: What They Can Mean For You? Karl Cremer, PharmD and AnnKatrin Petersen, MD, MS January 25, 2012 ClinicalStudy.org Owned and operated by PRI, Inc. 5927 Balfour Court, Suite 201 Carlsbad,
More informationClinical Research Service Provider Information Form
Clinical Research Service Provider Information Form General information Name of Organisation Real Regulatory Limited Contact information Head of Organisation: Main contact Name: Derval OCarroll Address:
More informationA Physician s consideration towards Biosimilars. João Eurico Fonseca
A Physician s consideration towards Biosimilars João Eurico Fonseca Disclosure I received unrestricted research grants or acted as a speaker for Abbvie, Amgen, BMS, Celtrion, Celgene, Janssen, MSD, Novartis,
More informationPARTNERS PARTNERS. Beyond the Barrier. Network in the biomedical Ecosystem and Robust Support system
PARTNERS Personalized & precision clinical trial consortium based on Advanced Research Tools, Network in the biomedical Ecosystem and Robust Support system PARTNERS Beyond the Barrier P A R T N E R S P
More informationRoche, Roche Molecular Diagnostics and more
, Molecular and more [Monte Wetzel, PhD] Patients have questions. We provide answers. Group Clear focus on Healthcare Innovation with two strong pillars Pharma Pharma Genentech Chugai Molecular Professional
More informationAntibody Discovery at Evotec
Antibody Discovery at Evotec - Overview - Evotec Antibodies Adding value to our partners research Innovative and flexible solutions from target ID to pre-clinical candidate The people A wide therapeutic
More information